VITAL-H: The $38M Trial Testing Rapamycin, Ozempic, and Farxiga Against Aging
BiohackingThe most rigorous clinical test of existing drugs against biological aging has begun enrollment. The VITAL-H trial — funded with up to $38 million from ARPA-H — is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy adults aged 60–65, measuring not whether they extend lifespan but whether they preserve the physical and mental capabilities that determine quality of life in older age.
Context
The longevity research field has debated for years which existing drugs are most promising for healthy aging in humans. Rapamycin has the longest research pedigree — a landmark 2009 study from the Barshop Institute demonstrated lifespan extension in elderly mice, one of the first controlled studies showing any drug could do that in mammals. Semaglutide (Ozempic/Wegovy) emerged more recently as a candidate based on cardiovascular and metabolic data well beyond its approved uses. Dapagliflozin (Farxiga) sits in a similar position: an SGLT2 inhibitor approved for diabetes, heart failure, and chronic kidney disease, with downstream effects on aging biology that researchers want to characterize in healthy people.
What’s been missing is a rigorous human trial testing all three at once, in a healthy aging population, against a shared outcome framework. VITAL-H is that trial.
The Detail
The Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) trial is led by the Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, partnering with Stanford, the Buck Institute, Columbia, and the South Texas Veterans Health Care System. It’s part of ARPA-H’s $144 million PROSPR program — one of the largest federal investments ever made in healthy longevity research.
The three drugs being tested:
Rapamycin is an mTOR inhibitor originally developed as an immunosuppressant. At low doses — lower than those used for transplant patients — it inhibits the mTOR pathway, which governs cell growth, metabolism, and aging processes. The Barshop Institute’s own 2009 research established the mouse lifespan data. VITAL-H tests whether the human translation holds.
Semaglutide (brand names: Ozempic, Wegovy) is a GLP-1 receptor agonist that mimics a gut hormone regulating blood sugar, appetite, and metabolism. Post-market cardiovascular data established benefits well beyond glucose management. Researchers selected it because it influences multiple age-related biological pathways simultaneously rather than targeting a single disease — a profile that matches how aging itself works.
Dapagliflozin (Farxiga) is an SGLT2 inhibitor that lowers blood sugar by enabling the kidneys to excrete excess glucose. Its approvals span type 2 diabetes, heart failure, and chronic kidney disease — and researchers hypothesize it may influence the biology connecting aging to chronic disease through mechanisms beyond glucose control.
The trial design: 726 adults aged 60–65, randomly assigned to one of four arms (one per drug plus placebo). Participants take one daily pill, wear a health-tracking ring monitoring activity, heart health, and sleep, and complete in-person assessments across San Antonio sites. Duration: three years of treatment plus six months of follow-up.
Rather than measuring lifespan — which would require decades — VITAL-H measures Intrinsic Capacity, the WHO framework assessing mobility, cognition, psychological function, vitality, and sensory abilities. The goal is to determine whether these drugs slow the functional decline that precedes chronic disease, not whether they extend raw survival.
Lead investigator Elena Volpi, MD, PhD: “Our population is living longer but with declining function, increased disability and reduced quality of life with major implications for healthcare utilization, caregiver burden and societal costs.”
The So What
VITAL-H matters for three reasons. First, all three drugs already have extensive human safety data — they’re not experimental compounds, they’re medications in widespread clinical use. The risk profile for testing in healthy older adults is substantially lower than novel compounds, and any positive signal translates directly to clinical practice without waiting for a new drug approval pathway.
Second, the trial specifically targets the 60–65 window — a point where measurable functional decline begins but chronic disease burden is still low. If interventions work better during this window than after disease onset, it defines an important targeting principle for clinical longevity protocols.
Third, the wearable component (health-tracking rings) creates a longitudinal dataset linking passive biometric data to drug response — the kind of data that has been missing from most longevity research and that could eventually support personalized treatment selection.
Results won’t arrive quickly. Three years of treatment followed by analysis means findings are likely 2029 or later. What VITAL-H establishes now is the methodological standard: large-scale, multi-arm, healthy-population, functional-outcome trials as the unit of evidence for anti-aging interventions.
Consult a qualified healthcare provider before considering any off-label use of the medications discussed. All three drugs are FDA-approved for specific indications; their use in healthy aging populations is investigational.
Photo by MART PRODUCTION on Pexels
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →